EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How latanoprost changed glaucoma management

Maria Francesca Cordeiro iD, Stefano Gandolfi, Konstantin Gugleta, Eduardo M Normando, Francesco Oddone

Acta Ophthalmologica · 2024

DOI: 10.1111/aos.15725 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Ophthalmologica, 2024. Verfasst von Maria Francesca Cordeiro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College Healthcare NHS Trust, Western Eye Hospital, London, UK. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle, Prostaglandins F, Synthetic, Glaucoma, Ocular Hypertension. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Viatris Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma is currently considered one of the leading causes of severe visual impairment and blindness worldwide. Topical medical therapy represents the treatment of choice for many glaucoma patients. Introduction of latanoprost, 25 years ago, with an entirely new mechanism of action from that of the antiglaucoma drugs used up to that time was a very important milestone. Since then, due mainly to their efficacy, limited systemic side effects and once daily dosing, prostaglandin analogues (PGAs) have become as the first‐choice treatment for primary open‐angle glaucoma. PGAs are in general terms well tolerated, although they are associated with several mild to moderate ocular and periocular adverse events. Among them, conjunctival hyperemia, eyelash changes, eyelid pigmentation, iris pigmentation and hypertrichosis around the eyes are the most prevalent. The objective of this paper is to review the role of PGAs in the treatment of glaucoma over the 25 years since the launch of Latanoprost and their impact on clinical practice outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glaucoma, Open-AngleProstaglandins F, SyntheticGlaucomaOcular HypertensionHumansLatanoprostAntihypertensive AgentsProstaglandins, SyntheticIntraocular Pressure

Stichwörter der Autor:innen

Latanoprostglaucomamedical treatmentopen-angle glaucomaprogressionprostaglandin analogues

Substanzen

LatanoprostProstaglandins F, SyntheticAntihypertensive AgentsProstaglandins, Synthetic

Autor:innen und Institutionen

  • Imperial College Healthcare NHS Trust, Western Eye Hospital, London, UK.
  • UCL Institute of Ophthalmology, London, UK.
  • Department of Surgery & Cancer, Irish Clinical Oncology Research Group, Imperial College London, London, UK.
  • Ophthalmology Unit, University Hospital of Parma, Parma, Italy.
  • University Hospital and University of Basel, Basel, Switzerland.
  • Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy.

ORCID-Profile: Maria Francesca Cordeiro

Förderung

  • Viatris Inc

Zitieren

APA

Cordeiro, M. F., Gandolfi, S., Gugleta, K., Normando, E. M., & Oddone, F. (2024). How latanoprost changed glaucoma management. Acta Ophthalmologica. https://doi.org/10.1111/aos.15725

Vancouver

Cordeiro MF, Gandolfi S, Gugleta K, Normando EM, Oddone F. How latanoprost changed glaucoma management. Acta Ophthalmologica. 2024. doi:10.1111/aos.15725

BibTeX
@article{Cordeiro2024,
  author = {Cordeiro, Maria Francesca and Gandolfi, Stefano and Gugleta, Konstantin and Normando, Eduardo M and Oddone, Francesco},
  title = {How latanoprost changed glaucoma management},
  journal = {Acta Ophthalmologica},
  year = {2024},
  doi = {10.1111/aos.15725}
}
Kostenlos starten →